Groups or subgroups | Comparisons (Subjects) | P Heterogeneity | SMD (95% CI) | P SMD |
---|---|---|---|---|
APOB | ||||
 All | 15 (5047) | 0.27 | 0.13 (0.06–0.20) | < 0.01 |
 Studies in HWE | 12 (4192) | 0.32 | 0.11 (0.04–0.19) | < 0.01 |
 Caucasian | 8 (3626) | 0.31 | 0.12 (0.03–0.21) | < 0.01 |
 Asian | 6 (1264) | 0.18 | 0.14 (−0.01–0.30) | 0.07 |
 CHD | 5 (2841) | 0.86 | 0.11 (0.03–0.18) | < 0.01 |
 Healthy or control | 9 (1975) | 0.06 | 0.12 (−0.03–0.26) | 0.11 |
 Case-control studies | 8 (3951) | 0.29 | 0.13 (0.04–0.21) | < 0.01 |
 Cohort studies | 7 (1096) | 0.23 | 0.15 (−0.001–0.30) | 0.05 |
TG | ||||
 All | 29 (7411) | < 0.01 | 0.03 (−0.04–0.11) | 0.37 |
 Studies in HWE | 24 (6576) | 0.02 | 0.04 (−0.05–0.12) | 0.44 |
 Male | 6 (3215) | 0.14 | 0.11 (−0.01–0.24) | 0.08 |
 Female | 4 (411) | 0.16 | 0.22 (−0.10–0.53) | 0.18 |
 Caucasian | 12 (4691) | 0.11 | 0.02 (−0.11–0.07) | 0.62 |
 Asian | 11 (1281) | 0.13 | 0.21 (0.06–0.36) | < 0.01 |
 CHD | 8 (3138) | 0.02 | 0.15 (−0.01–0.32) | 0.07 |
 Healthy or control | 18 (3274) | 0.04 | −0.02 (−0.13–0.08) | 0.70 |
 Case-control studies | 15 (4538) | 0.12 | 0.09 (−0.003–0.18) | 0.06 |
 Cohort studies | 14 (2873) | 0.03 | 0.03 (−0.04–0.11) | 0.60 |
TC | ||||
 All | 32 (7875) | < 0.01 | 0.17 (0.07–0.26) | < 0.01 |
 Studies in HWE | 23 (6133) | < 0.01 | 0.18 (0.04–0.33) | 0.01 |
 Male | 7 (3220) | 0.72 | 0.14 (0.07–0.21) | < 0.01 |
 Female | 5 (470) | < 0.01 | 0.74 (−0.26–1.75) | 0.15 |
 Caucasian | 14 (4598) | 0.34 | 0.13 (0.06–0.20) | < 0.01 |
 Asian | 13 (1924) | < 0.01 | 0.33 (0.06–0.60) | 0.02 |
 CHD | 10 (3455) | 0.42 | 0.12 (0.05–0.19) | < 0.01 |
 Healthy or control | 15 (2577) | < 0.01 | 0.23 (0.05–0.40) | 0.01 |
 Case-control studies | 14 (4526) | < 0.01 | 0.22 (0.03–0.41) | 0.02 |
 Cohort studies | 18 (3349) | 0.15 | 0.14 (0.05–0.23) | < 0.01 |
LDL-C | ||||
 All | 30 (5658) | < 0.01 | 0.15 (0.07–0.23) | < 0.01 |
 Studies in HWE | 23 (4233) | < 0.01 | 0.15 (0.04–0.25) | < 0.01 |
 Male | 5 (955) | 0.85 | 0.07 (−0.06–0.21) | 0.27 |
 Female | 4 (411) | 0.04 | 0.01 (−0.38–0.41) | 0.95 |
 Caucasian | 13 (2562) | 0.38 | 0.14 (0.05–0.23) | < 0.01 |
 Asian | 12 (1817) | < 0.01 | 0.18 (0.00–0.35) | 0.05 |
 CHD | 7 (879) | 0.09 | 0.15 (−0.04–0.34) | 0.12 |
 Healthy or control | 19 (3764) | < 0.01 | 0.13 (0.02–0.24) | 0.02 |
 Case-control studies | 15 (2807) | 0.07 | 0.12 (0.02–0.23) | 0.03 |
 Cohort studies | 15 (2851) | < 0.01 | 0.18 (0.06–0.31) | < 0.01 |
HDL-C | ||||
 All | 27 (5124) | < 0.01 | −0.04 (−0.12–0.05) | 0.40 |
 Studies in HWE | 21 (3750) | < 0.01 | −0.07 (−0.18–0.05) | 0.25 |
 Male | 5 (703) | 0.10 | −0.06 (−0.30–0.17) | 0.58 |
 Female | 4 (411) | 0.57 | −0.01 (−0.23–0.21) | 0.91 |
 Caucasian | 9 (1881) | 0.30 | −0.02 (−0.13–0.09) | 0.77 |
 Asian | 13 (1924) | < 0.01 | −0.10 (−0.26–0.06) | 0.21 |
 CHD | 7 (879) | 0.05 | −0.06 (−0.27–0.14) | 0.55 |
 Healthy or control | 18 (3605) | 0.01 | −0.03 (−0.13–0.08) | 0.65 |
 Case-control studies | 13 (2267) | 0.02 | −0.07 (−0.20–0.06) | 0.31 |
 Cohort studies | 14 (2854) | 0.06 | −0.01 (−0.12–0.10) | 0.89 |